Cardiol Therapeutics Announces Year-End 2023 Update on Operations [Yahoo! Finance]
Cardiol Therapeutics Inc. - Class A Common Shares (CRDL)
Company Research
Source: Yahoo! Finance
CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis, which includes recurrent pericarditis Exceeded 50% enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients with acute myocarditis; study expected to reach full enrollment during Q3 2024 Data presented at the HFSA Annual Scientific Sessions 2023 demonstrated that the API in Cardiol's novel CRD-38 formulation attenuates harmful fat distribution and key markers of cardiac inflammation and remodelling in a model of heart failure with preserved ejection fraction Cash and cash equivalents of $34.9 million as of December 31, 2023, which funds operations into 2026 Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, to
Show less
Read more
Impact Snapshot
Event Time:
CRDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDL alerts
High impacting Cardiol Therapeutics Inc. - Class A Common Shares news events
Weekly update
A roundup of the hottest topics
CRDL
News
- Cardiol Therapeutics Inc. (NASDAQ: CRDL) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis [Yahoo! Finance]Yahoo! Finance
- Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis [Yahoo! Finance]Yahoo! Finance
- Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth? [Yahoo! Finance]Yahoo! Finance
CRDL
Analyst Actions
- 4/22/24 - HC Wainwright
CRDL
Sec Filings
- 4/26/24 - Form 6-K
- 4/2/24 - Form 6-K
- 4/1/24 - Form 20-F
- CRDL's page on the SEC website